RESPIRERX PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 11, 2023, RespireRx Pharmaceuticals Inc. (the "Company") formed an Australian subsidiary, ResolutionRx Ltd ("ResolutionRx"), an unlisted public company.

The press release dated January 12, 2023 announcing the formation of ResolutionRx by the Company, which includes, among other things, further information about the intended purpose of ResolutionRx, is attached as Exhibit 99.1 to this Current Report on Form 8-K.

A copy of the Certificate of Registration of a Company, ResolutionRx Ltd is attached as Exhibit 99.2 to this Current Report of Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which follows, and is incorporated herein by reference.

© Edgar Online, source Glimpses